The Holy Grail: Solid Tumor Efficacy by Proteasome Inhibition.
Proteasome inhibitors have revolutionized the treatment of multiple myeloma but have had disappointing results when treating solid tumors. The work of Weyburne et al. (2017), published in this issue of Cell Chemical Biology, sheds some light on this conundrum and suggests a novel approach to achieve solid tumor efficacy.